3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
5
Cholangiocarcinoma
4
Stomach Neoplasms
2
Rectal Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Ovarian Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Interventions
Cisplatin
6
Gemcitabine
5
Oxaliplatin
3
Irinotecan
3
durvalumab
2
Folfox protocol
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
trastuzumab deruxtecan
1
toripalimab
1
pembrolizumab
1
niraparib
1
neratinib
1
ivosidenib
1
futibatinib
1
fludarabine
1
envafolimab
1
encorafenib
1
brigimadlin
1
binimetinib
1
Trastuzumab
1
Pemetrexed
1
Nivolumab
1
Leucovorin
1
Docetaxel
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Folfox protocol
×
30 days
×
Clear all
NCT06529718
2026-05-19
SEVILLA
UNICANCER
Phase 2
Recruiting
72 enrolled
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled